The Hidden Cost of Shelf Life: New Study Links Common Food Preservatives to Cardiovascular Risk on September 20, 2026 Posted by
Beyond the Stigma: Redefining Health Anxiety in the Modern Diagnostic Era on September 20, 2026 Posted by
The Golden Standard: America’s Top Seafood Chains for the Ultimate Fried Shrimp and Fries Experience on September 20, 2026 Posted by
Semaglutide Shows Robust Cardiovascular and Quality-of-Life Benefits in Frail Patients: New Analysis of SELECT Trial Data on September 20, 2026 Posted by
Beyond the Diagnosis: The Intersection of Neurodivergence and Cultural Identity in Mental Healthcare on September 20, 2026 Posted by
Clash of Southeast Asian Titans: Comprehensive Analysis and Predictions for Malaysia vs. Vietnam (August 16) on September 20, 2026 Posted by
A New Frontier in Cardiology: Experimental Oral Drug Enlicitide Shows Promise in Sashing Cholesterol Levels on September 20, 2026 Posted by
The Hidden Cost of Shelf Life: New Study Links Common Food Preservatives to Cardiovascular Risk on September 20, 2026 Posted by
Beyond the Stigma: Redefining Health Anxiety in the Modern Diagnostic Era on September 20, 2026 Posted by
The Golden Standard: America’s Top Seafood Chains for the Ultimate Fried Shrimp and Fries Experience on September 20, 2026 Posted by
Semaglutide Shows Robust Cardiovascular and Quality-of-Life Benefits in Frail Patients: New Analysis of SELECT Trial Data on September 20, 2026 Posted by
Posted in Medical Innovations The Patent Perimeter: Amgen, Antitrust, and the Future of Drug Monopoly Litigation on August 31, 2026
Posted in Sleep Health Amgen Accelerates Phase 3 MARITIME-OSA Trials: A New Frontier in Treating Obesity-Linked Sleep Apnea on August 31, 2026
Posted in Digital Health Tools AstraZeneca and Amgen’s Tezspire Poised to Challenge Market Leaders in Eosinophilic Esophagitis Treatment on August 27, 2026
Posted in Medical Innovations Tezspire’s Clinical Success in Eosinophilic Esophagitis Marks a Potential New Era for AstraZeneca and Amgen on August 27, 2026
Posted in Sleep Health Amgen Advances Strategic Pipeline: MARITIME-OSA Trials Seek to Revolutionize Sleep Apnea Treatment on August 24, 2026
Posted in Sleep Health Amgen Advances Strategic Pipeline: Phase 3 MARITIME-OSA Trials Target the Intersection of Obesity and Sleep Apnea on August 17, 2026
Posted in Sleep Health Amgen Advances Pivotal Phase 3 MARITIME-OSA Trials for Investigational Obesity and Sleep Apnea Therapy on August 5, 2026
Posted in Medical Innovations High-Stakes Battle: Amgen Fights to Save Vasculitis Drug Tavneos from FDA Withdrawal on July 26, 2026
Posted in Digital Health Tools A New Era in Thyroid Eye Disease: FDA Approves Viridian’s Lumvoa, Challenging the Amgen Monopoly on June 29, 2026
Posted in Digital Health Tools Regulatory Crisis Deepens: Amgen’s Tavneos Faces Global Withdrawal Amid Data Integrity Concerns on June 27, 2026
